Tags Archive Navigation
icon
-
Media ReleaseNovartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
-
Media ReleaseNovartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
-
Media ReleaseNovartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024
-
Media ReleaseNovartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
-
Media ReleaseNew Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
-
Media ReleaseNew Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
-
StoryDrug delivery, service delivery, and the future of cancer care
-
Media ReleaseNovartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
-
Media ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
-
Media ReleaseAktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
-
Media ReleaseNovartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 31
- › Next page